An integrative analytical approach designed for feasible tranexamic acid assay using o‐phthalaldehyde as a fluorogenic probe: applications to tablets, ampoules, and urine

Antifibrinolytic tranexamic acid (TRX) suppresses plasminogen activation to plasmin in a competitive way. TRX is approved for the management of heavy menstrual periods, hereditary angioedema, hemophilia, postpartum hemorrhage, surgery, tooth extraction, and severe blood loss after acute trauma. Here...

Ausführliche Beschreibung